A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 in Patients With Moderately to Severely Active Ulcerative Colitis
A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 in Patients With Moderately to Severely Active Ulcerative Colitis
This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active ulcerative colitis (UC).
Inclusion Criteria:
Exclusion Criteria:
Dothan, Alabama 36305, United States
San Antonio, Texas 78212, United States
Chesapeake, Virginia 23320, United States
Ciudad Autonoma Buenos Aires, C1061AAS, Argentina
Ciudad Autonoma Buenos Aires, C1128AAE, Argentina
Shanghai, 200127, China
Wuhan, 430022, China
Mexico, Tlaxcala 06726, Mexico
??czna, 21-010, Poland
?ód?, 92-213, Poland
Toru?, 87-100, Poland
Wroc?aw, 53-149, Poland
Wroc?aw, 54-239, Poland
Zamo??, 22-400, Poland
Changhua, Changhua County 50006, Taiwan
Bangkok, 10330, Thailand
Bangkok, 10700, Thailand
Songkhla, 90110, Thailand